Thrombocytopenic Purpura

In this video, Iberia Romina Sosa, MD, PhD, discusses the results of a study presented at ASH Annual Meeting and Exposition, which examined the use of obinutuzumab in patients with thrombotic thrombocytopenic purpura.

Among patients with congenital thrombotic thrombocytopenic purpura, prophylactic therapy with recombinant ADAMTS13 restored normal levels of the enzyme, according to results of a randomized phase 3 study.